兰州大学机构库 >学院待认领
腺病毒介导的IL-28B对U14宫颈癌皮下移植瘤小鼠调节性T细胞的影响及抗肿瘤作用的研究
Alternative TitleThe Research of Adenovirus Mediated IL-28B on Regulatory T cells and Anti-Tumor Effect of U14 Cervical Subcutaneous Transplantation Tumor
陈小芸
Thesis Advisor郭钰珍
2015-05-18
Degree Grantor兰州大学
Place of Conferral兰州
Degree Name硕士
KeywordIL-28B 腺病毒 宫颈癌 U14细胞 Tregs
Abstract目的: 研究腺病毒介导的IL-28B(Ad-mIL-28B)对U14宫颈癌皮下移植瘤小鼠脾脏中调节性T细胞(Tregs)的影响及其抗肿瘤的作用。 方法:体外培养HEK293细胞;建立小鼠U14宫颈癌腹水模型和皮下移植瘤模型;观察并测定Ad-mIL-28B处理后小鼠(Babl/C和c57bl/6j)U14宫颈癌皮下移植瘤瘤体的生长、瘤重及脾脏中CD4+CD25+Foxp3+Tregs的变化 。 结果:1.采用CPE法测定病毒滴度后,病毒(Ad-mIL-28B和Ad-EGFP)滴度均为:108PFU/100μL。2.成功建立了小鼠(Babl/C和c57bl/6j)U14宫颈癌腹水模型和皮下移植瘤模型。3.与PBS组相比,Ad-mIL-28B组脾脏中的CD4+CD25+Foxp3+Tregs在淋巴细胞中所占的比例减少;Ad-mIL-28B组能够明显的减小移植瘤的体积;Ad-mIL-28B组能够明显的减小移植瘤的体积;Ad-mIL-28B组小鼠移植瘤瘤重明显减轻;Ad-mIL-28B能明显的抑制移植瘤的生长;Ad-mIL-28B组脾脏和肺脏指数的变化与对照组相比,有统计学意义,而肝脏指数的变化无明显的统计学意义。4.HE染色结果表明,Ad-mIL-28B组肿瘤组织中的异型性的肿瘤细胞的数量与对照组相比明显减少,肺脏和肝脏组织未见明显的瘤细胞转移。 结论: Ad-mIL-28B能够降低U14宫颈癌皮下移植瘤小鼠(Babl/C和c57bl/6j)脾脏中的CD4+CD25+Foxp3+Tregs,并且能抑制小鼠(Babl/C和c57bl/6j)U14宫颈癌皮下移植瘤的生长。 关键词: IL-28B,腺病毒,宫颈癌,U14细胞,Tregs
Other AbstractObjective: To investigate adenovirus mediated IL-28B(Ad-mIL-28B) on regulatory T cells in the spleen and anti-tumor effect of mice U14 cervical subcutaneous transplantation tumor. Methods: HEK293 cells were cultured in vitro; Adenoviral (Ad-mIL-28B and Ad-EGFP) titer was determined by the method of microdose cytopathogenic efficiency (CPE); Using mice U14 cervical cancer cells to establish cervical cancer ascites model and subcutaneous transplantation tumor model; Observe the tumor size then calculate tumor weight,tumor inhibitory rate,lung index,spleen index and liver index after Ad-mIL-28B treatment; To detect CD4+CD25+Foxp3+Tregs of Babl/C and c57bl/6j mice in the spleen after Ad-mIL-28B treatment by flow cytometry. Results: 1.Adenoviral(Ad-mIL-28B and Ad-EGFP) titer was determined by CPE and the virus drops are 108PFU/100μL. 2.We successfully established mice (Babl/C and c57bl/6j) U14 cervical cancer ascites model and subcutaneous transplantation tumor model. 3.The proportion of CD4+CD25+Foxp3+TregsAd-mIL-28B treatment significantly decreased the number of CD4+CD25+Foxp3+Tregs compared with PBS group(p=0.034). 4.The tumor volume of Ad-mIL-28B group significantly suppressed compared with PBS group(p=0.008). 5.The tumor volume of Ad-mIL-28B group significantly suppressed compared with PBS group(p=0.001). 6.Tumor weight of c57bl/6j mice in Ad-mIL-28B, Ad-EGFP and PBS group is 78.4g±23.3g,200.1g±90.3g and 303.2g±123.2g. Ad-mIL-28B treatment significantly decreased the weight of tumor compared with PBS group (p=0.049). 7.Ad-mIL-28B treatment significantly inhibited the tumor growth compared with control group(p=0.000). 8.The spleen and lung index changes of Ad-mIL-28B group were statistically significant(p<0.05),while the liver index change has no obvious statistical significance. 9.There was a significant decrease in the size of tumor tissue and the number of heteromorphisms tumor cells. The tumor metastasis in lung and liver of the Ad-mIL-28B group also decreased. Conclusion: Ad-mIL-28B can reduce CD4+CD25+Foxp3+Tregs and inhibit growth of U14 cervical subcutaneous transplantation tumor growth.Ad-mIL-28B may inhibit the growth and metastasis of cervical cancer by inhibiting the expression of CD4+CD25+Foxp3+Tregs. Key words:IL-28B, Adenovirus, Cervical cancer, U14 cells, Regulatory T cells
URL查看原文
Language中文
Document Type学位论文
Identifierhttps://ir.lzu.edu.cn/handle/262010/222512
Collection学院待认领
Affiliation临床医学院
Recommended Citation
GB/T 7714
陈小芸. 腺病毒介导的IL-28B对U14宫颈癌皮下移植瘤小鼠调节性T细胞的影响及抗肿瘤作用的研究[D]. 兰州. 兰州大学,2015.
Files in This Item:
There are no files associated with this item.
Related Services
Recommend this item
Bookmark
Usage statistics
Export to Endnote
Altmetrics Score
Google Scholar
Similar articles in Google Scholar
[陈小芸]'s Articles
Baidu academic
Similar articles in Baidu academic
[陈小芸]'s Articles
Bing Scholar
Similar articles in Bing Scholar
[陈小芸]'s Articles
Terms of Use
No data!
Social Bookmark/Share
No comment.
Items in the repository are protected by copyright, with all rights reserved, unless otherwise indicated.